Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | MAOB | P27338 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29633530 | 0.82 | MAPT (1.00) | L3MBTL1MAPTCYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL701961 | 0.82 | MAPT (1.00) | L3MBTL1MAPTCYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL21668583 | 0.82 | MAPT (0.74) | L3MBTL1MAPTCYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL1559781 | 0.81 | MAPT (0.72) | L3MBTL1MAPTCYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL31069853 | 0.81 | MAPT (0.72) | L3MBTL1MAPTCYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL9123233 | 0.80 | MAPT (0.71) | L3MBTL1MAPTCYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL9120538 | 0.77 | MAPT (0.67) | L3MBTL1MAPTCYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL24162183 | 0.77 | MAPT (0.67) | L3MBTL1MAPTCYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL19267889 | 0.77 | SMN1; SMN2 (0.67) | L3MBTL1MAPTCYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL8465903 | 0.76 | MAPT (0.70) | L3MBTL1MAPTCYP2C9CYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142646-A1 | Novel Compounds 621 | ASTRAZENECA AB (SE) | 2012-06-07 | — | — | US | disclosed |
| US-20100056508-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142646-A1 | Novel Compounds 621 | AR, ADRA1D, ADRA1B | L3MBTL1 2855/4885MAPT 2725/4885CYP2C9 1279/4885 |
| US-20100056508-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | ADRB2, ADRB1, ADRA2A | L3MBTL1 2364/4885MAPT 1010/4885CYP2C9 1911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.